I’m a researcher who is a part of the Dermatology Service at Memorial Sloan Kettering Cancer Center (MSK).
I have extensive experience in developing quantitative image analysis and using artificial intelligence (AI) tools for the non-invasive diagnosis of skin diseases. I am an expert in using machine learning, computer vision, and signal processing, for dermatological imaging.
This includes using tools such as dermoscopy, clinical imaging, and total body photography. It also includes microscopic tools such as reflectance confocal microscopy (RCM), an imaging technology that uses laser light to look at your skin cells. All these tools help us detect skin cancers and other skin conditions.
I have a proven track record of leading and contributing to large, federally funded international research projects and translating novel algorithms from the lab into clinical practice.
Master of Science, Signal Processing, Bilkent University, Turkey
Bachelor of Science, Electrical & Electronics Engineering, Bilkent University, Turkey
- Kurtansky, N.R., Gillis, M.C., Codella, N.C.F. et al. Automated triage of cancer-suspicious skin lesions with 3D total-body photography. npj Digit. Med. 8, 708 (2025).
- Kentley J, Kurtansky N, Jain M, … Kose K. Non-invasive diagnosis of melanoma using machine learning and reflectance confocal microscopy. Journal of Investigative Dermatology. 2025.
- Kose K, Bozkurt A, Alessi-Fox C, et al. Segmentation of cellular patterns in confocal images of melanocytic lesions in vivo via a multiscale encoder-decoder network (MED-Net). Med Image Anal. 2020;67:101841.
- Kose K, Gou M, Yélamos O, et al. Automated video-mosaicking approach for confocal microscopic imaging in vivo: an approach to address challenges in imaging living tissue and extend field of view. Sci Rep. 2017;7(1):10759.
- Kurtansky NR, D’Alessandro BM, Gillis MC, … Kose K, et al. The SLICE-3D dataset: 400,000 skin lesion image crops extracted from 3D TBP for skin cancer detection. Sci Data. 2024;11:884.
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Kivanc Kose discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures